Neamți Lidia, Gheorghe Simona R, Ventuneac Amalia, Drugan Tudor, Drugan Cristina, Silaghi Ciprian N, Ciobanu Lidia, Crăciun Alexandra M
Department of Medical Biochemistry, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
Department of Internal Medicine, 1 Medical Clinic, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400006 Cluj-Napoca, Romania.
Biomedicines. 2024 Aug 2;12(8):1733. doi: 10.3390/biomedicines12081733.
Inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), are chronic conditions marked by persistent inflammation, impacting patients' quality of life. This study assessed differences in coffee consumption between CD and UC patients and its potential effects on the subjective perception and objective changes in inflammation markers in these two categories of patients. Using questionnaires, coffee consumption patterns, and perceived symptom effects were evaluated. Biological samples were collected to measure the following inflammatory markers: leukocytes, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and fecal calprotectin (FC). Among 148 patients, 60% reported regular coffee consumption, with no significant difference between CD and UC patients. While 45.93% perceived no impact on symptoms, 48% of those reporting exacerbation continued their regular coffee consumption. FC values were significantly lower in coffee consumers than in non-consumers ( < 0.05), particularly in those consuming natural coffee ( < 0.001), and the case was observed for UC patients ( < 0.05). No significant differences were observed in other inflammatory markers, regardless of coffee type, frequency, or milk addition. This study highlights the commonality of coffee consumption among IBD patients and the association of lower FC levels with coffee consumption, especially in UC patients, suggesting that coffee may influence intestinal inflammatory responses.
炎症性肠病（IBD），包括克罗恩病（CD）和溃疡性结肠炎（UC），是一种以持续炎症为特征的慢性疾病，会影响患者的生活质量。本研究评估了CD患者和UC患者在咖啡饮用方面的差异，以及咖啡对这两类患者炎症标志物主观感受和客观变化的潜在影响。通过问卷调查评估了咖啡饮用模式和感知到的症状影响。采集生物样本以测量以下炎症标志物：白细胞、C反应蛋白（CRP）、红细胞沉降率（ESR）和粪便钙卫蛋白（FC）。在148名患者中，60%报告有规律饮用咖啡，CD患者和UC患者之间无显著差异。虽然45.93%的患者认为咖啡对症状无影响，但在报告症状加重的患者中，48%仍继续有规律地饮用咖啡。咖啡饮用者的FC值显著低于非饮用者（<0.05），尤其是饮用纯咖啡的人（<0.001），UC患者中也观察到这种情况（<0.05）。无论咖啡类型、饮用频率或是否添加牛奶，其他炎症标志物均未观察到显著差异。本研究强调了IBD患者中咖啡饮用的普遍性，以及较低的FC水平与咖啡饮用之间的关联，尤其是在UC患者中，这表明咖啡可能会影响肠道炎症反应。
